As of June 10, 2025, Immune Pharmaceuticals Inc (IMNPQ) reports a Gross Margin of 26.60%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Immune Pharmaceuticals Inc's Gross Margin
Over recent years, Immune Pharmaceuticals Inc's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2017-12-31 | 26.60% |
| 2016-12-31 | 94.87% |
| 2015-12-31 | 26.60% |
| 2014-12-31 | -1.01% |
| 2013-12-31 | 100.00% |
This fluctuation highlights how Immune Pharmaceuticals Inc manages its operational efficiency and pricing power over time.
Comparing Immune Pharmaceuticals Inc's Gross Margin to Peers
To better understand Immune Pharmaceuticals Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Immune Pharmaceuticals Inc (IMNPQ) | 26.60% |
| Rasna Therapeutics Inc (RASP) | 7775.20% |
| PZ Wind Down Inc (PZRXQ) | 7775.20% |
| Peak Pharmaceuticals Inc (PKPH) | 7775.20% |
| Viewbix Inc (VBIX) | 7775.20% |
| Phio Pharmaceuticals Corp (PHIO) | 7775.20% |
Compared to its competitors, Immune Pharmaceuticals Inc's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.